SCHEMBL10045815

SCHEMBL10045815

COC(=O)c1coc(C(CO[Si](C(C)C)(C(C)C)C(C)C)NC(=O)c2coc(C(CCCCNC(=O)OC(C)(C)C)NC(=O)OCc3ccccc3)n2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
C3AR1 Q16581 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 2/20 0.40
MAPK1 P28482 1/20 0.40
KLK7 P49862 2/20 0.40
KLK5 Q9Y337 2/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RECQL P46063 1/20 0.40
SYK P43405 1/20 0.40
PAX8 Q06710 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10045816 0.91 MAPT (0.59) MAPTC3AR1L3MBTL1POLBMAPK1
SCHEMBL10045813 0.91 MAPT (0.67) MAPTL3MBTL1POLBMAPK1KLK7
SCHEMBL10045825 0.87 MAPT (0.56) MAPTC3AR1L3MBTL1POLBMAPK1
SCHEMBL800816 0.84 MAPT (0.54) MAPTL3MBTL1POLBMAPK1KLK7
SCHEMBL10045814 0.84 MAPT (0.69) MAPTL3MBTL1POLBMAPK1KLK7
SCHEMBL10045817 0.83 MAPT (0.59) MAPTL3MBTL1POLBMAPK1KLK7
SCHEMBL10045819 0.83 MAPT (0.52) MAPTC3AR1L3MBTL1POLBMAPK1
SCHEMBL10045823 0.79 C3AR1 (0.49) MAPTC3AR1L3MBTL1MEN1KMT2A
SCHEMBL10045820 0.78 MAPT (0.61) MAPTL3MBTL1POLBMAPK1KLK7
SCHEMBL13953737 0.77 MAPT (0.52) MAPTL3MBTL1POLBMAPK1KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093235-B2 Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2012-01-10 US disclosed
US-20090156627-A1 THERAPEUTIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156627-A1 THERAPEUTIC COMPOUNDS TOP2B, DDB1, RECQL MAPT 1974/4885C3AR1 2510/4885L3MBTL1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.